Panacela Labs
Fostering biomedical breakthroughs for oncology and rare diseases through global collaboration
Fostering biomedical breakthroughs for oncology and rare diseases through global collaboration
Panacela Labs is a collaborative enterprise fostering biomedical breakthroughs for oncology and rare diseases through global collaboration. Founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company specializing in oncology and orphan drug development, and Open Joint Stock Company “RUSNANO,” the largest Russian investment entity, in partnership with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia, and Cleveland Clinic Foundation. Cleveland BioLabs holds a 54.6% ownership stake in Panacela Labs. The company is located within the Innovation Center "Skolkovo." Their most recent investment was a $2.90M Series B investment on 24 December 2015 from Cleveland BioLabs and RUSNANO. Panacela Labs operates in the Biotechnology and Health Care sectors, positioning itself at the intersection of cutting-edge science and investment opportunities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $2.90M | 2 | Cleveland BioLabs, RUSNANO | 24 Dec 2015 |
| Series A | $37.00M | 2 | Cleveland BioLabs, RUSNANO | 07 Oct 2011 |
No recent news or press coverage available for Panacela Labs.
We care about your data, and we'd love to use cookies make your experience better.
